Sinopharm Group Co. Ltd. (Sinopharm) disclosed that its Shenzhen-listed subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord), recorded a robust earnings rebound for the year ended 31 December 2025.

Revenue eased 1.29% year-on-year to RMB73.42 billion, yet net profit attributable to shareholders surged 76.80% to RMB1.14 billion. After excluding non-recurring items, net profit expanded 88.53% to RMB1.10 billion, underscoring an improvement in core profitability.

Basic and diluted earnings per share rose to RMB2.04 from RMB1.15 a year earlier, while weighted average return on equity improved by 2.59 percentage points to 6.26%.

Operating cash inflow declined 49.91% to RMB1.64 billion, reflecting a normalisation from the elevated RMB3.27 billion generated in 2024.

On the balance-sheet front, total assets increased 3.24% to RMB49.10 billion, and net assets attributable to shareholders advanced 5.32% to RMB18.61 billion.

Management attributed the profit recovery primarily to a RMB0.69 billion reduction in impairment charges on goodwill and intangible assets, alongside lower fixed expenses such as labour and rent following store-network optimisation.